The gap between a drug’s sticker price and what anyone actually pays is where most commercial strategy either gets built or falls apart. Understanding how drug pricing actually works in the US — not the simplified version, but the real mechanics — is a prerequisite for anyone managing a pharma brand, negotiating payer contracts, or advising on launch strategy.
WAC Is Not the Price Anyone Pays
Wholesale acquisition cost (WAC) is the manufacturer’s published list price — the number that appears in press releases and Senate hearings. It’s not the price patients pay, it’s not the price payers pay, and it’s not the revenue the manufacturer collects. WAC is the starting point for a series of deductions that can reduce realized revenue by 30% to 60% or more depending on the product, channel, and therapeutic category.
Net price — what the manufacturer actually receives after rebates, discounts, and fees — is the number that matters for brand P&L modeling. The spread between WAC and net has widened substantially over the past decade, driven primarily by PBM rebate demands in competitive categories.
The PBM Layer: Where Formulary Access Gets Negotiated
Pharmacy benefit managers sit between manufacturers and payers, managing formularies and negotiating rebates on behalf of health plans. The three largest — CVS Caremark, Express Scripts, and OptumRx — collectively manage pharmacy benefits for the majority of commercially insured Americans.
Rebates are the mechanism through which manufacturers buy formulary placement. A manufacturer offering a 40% rebate on WAC to secure preferred tier status effectively reduces its net price by 40% — in exchange for preferential access to covered lives. In categories where multiple branded drugs compete (diabetes, inflammatory disease, cardiovascular), rebate demands escalate as each competitor bids for preferred placement. This is why WAC keeps rising even as net prices are stagnant or falling: the published price is a negotiating anchor, not a revenue signal.
Government Channels Have Their Own Rules
Medicaid best price requires manufacturers to extend the lowest price given to any commercial payer to state Medicaid programs. This creates a floor problem: aggressive rebate offers to commercial payers drag down Medicaid reimbursement. The Inflation Reduction Act added another layer by authorizing Medicare to directly negotiate prices for high-spend drugs — a first in the program’s history that fundamentally changes the pricing calculus for assets likely to face negotiation selection.
The 340B program requires manufacturers to provide discounted drugs to covered entities — hospitals and clinics serving low-income patients. The program has expanded far beyond its original intent and is now a significant revenue drain for many manufacturers, particularly in oncology and specialty categories where covered entities represent a large share of the prescriber base.
The Patient Access Layer
Patient out-of-pocket cost is determined by their benefit design — their deductible, copay tier, and out-of-pocket maximum — not by the drug’s WAC. Manufacturers use copay assistance programs to reduce patient cost-sharing in commercial plans, effectively subsidizing access for insured patients whose plans place a product on a non-preferred tier. Copay accumulator programs, adopted by many large plans, limit the extent to which manufacturer copay assistance counts toward patients’ deductibles — a design feature that shifts cost back to patients and reduces the value of copay cards.
The commercial read: a drug priced at $8,000 per month with a 50% net-to-WAC ratio and a copay card program covering 90% of patient out-of-pocket — after accounting for copay accumulator impact, channel fees, and distribution costs — may generate realized revenue per unit that looks very different from the sticker price. Brand teams that don’t model this in detail are flying blind on launch economics.
For a deeper read on how the IRA is changing the negotiation layer, see our Drug Pricing & Market Access Hub.
